• +1-646-491-9876
    • +91-20-67278686

    Search

    Toll Like Receptor 8-Pipeline Review H1 2017

    Toll Like Receptor 8-Pipeline Review H1 2017

    • Report Code ID: RW0001834420
    • Category Pharmaceuticals
    • No. of Pages 63
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2017

    Summary

    Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

    Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 4 and 1 respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Dermatology, Gastrointestinal, Respiratory and Musculoskeletal Disorders which include indications Actinic (Solar) Keratosis, Cutaneous T-Cell Lymphoma, Solid Tumor, Systemic Lupus Erythematosus, Allergic Rhinitis, Colorectal Cancer, Crohn's Disease (Regional Enteritis) , Dermatomyositis, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Inflammatory Bowel Disease, Melanoma, Pancreatic Cancer, Perennial Allergic Rhinitis, Peritoneal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rheumatoid Arthritis, Seasonal Allergic Rhinitis, Sicca Syndrome (Sjogren) , Ulcerative Colitis and Warts.

    The latest report Toll Like Receptor 8 - Pipeline Review, H1 2017, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
    - The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Toll Like Receptor 8 (CD288 or TLR8) - Overview
    Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
    Dynavax Technologies Corp
    Galderma SA
    Gilead Sciences Inc
    Idera Pharmaceuticals Inc
    Janus Biotherapeutics Inc
    MedImmune LLC
    VentiRx Pharmaceuticals Inc
    Vivelix Pharmaceuticals Ltd
    Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
    854-A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DV-1001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-9688 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMO-8400 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMO-9200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JB-6121 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MEDI-9197 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    motolimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    resiquimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RSLV-132 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VTX-1463 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VTX-294 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VTX-763 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
    Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
    Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
    Featured News & Press Releases
    Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus
    Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination
    May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference
    Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study
    Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom's Macroglobulinemia
    Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis
    Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom's Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting
    May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors
    Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer
    Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma
    Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia
    Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting
    Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings
    Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200
    Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Dynavax Technologies Corp, H1 2017
    Pipeline by Galderma SA, H1 2017
    Pipeline by Gilead Sciences Inc, H1 2017
    Pipeline by Idera Pharmaceuticals Inc, H1 2017
    Pipeline by Janus Biotherapeutics Inc, H1 2017
    Pipeline by MedImmune LLC, H1 2017
    Pipeline by VentiRx Pharmaceuticals Inc, H1 2017
    Pipeline by Vivelix Pharmaceuticals Ltd, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Dynavax Technologies Corp
    Galderma SA
    Gilead Sciences Inc
    Idera Pharmaceuticals Inc
    Janus Biotherapeutics Inc
    MedImmune LLC
    VentiRx Pharmaceuticals Inc
    Vivelix Pharmaceuticals Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//toll-like-receptor-8-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//toll-like-receptor-8-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//toll-like-receptor-8-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments